Revenue and net profit grew year-over-year for the quarter ended June 30, 2025, with EPS also rising. Auditors found no material misstatements, and the company continues to operate solely in the pharmaceuticals segment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.